Immunological Drivers and Potential Novel Drug Targets for Major Psychiatric, Neurodevelopmental, and Neurodegenerative Conditions

Competing Interest Statement

JWR is a full-time employee of Boehringer Ingelheim but undertook all relevant work when at the University of Bristol. TGR is a full-time employee of GlaxoSmithKline outside of this work. No funding body has influenced data collection, analyses, or their interpretation.

Funding Statement

GMK, HJJ, CD, ES, GDS, GH, TRG, work within the MRC Integrative Epidemiology Unit at the University of Bristol, which is supported by the Medical Research Council (MC_UU_00032/1, 3, & 6). CD is supported by a postdoctoral fellowship from the South-Eastern Norway Regional Health Authority (2024078). GMK acknowledges additional funding support from the Wellcome Trust (201486/Z/16/Z and 201486/B/16/Z), Medical Research Council (MR/W014416/1; MR/S037675/1; and MR/Z50354X/1) and the UK National Institute of Health and Care Research (NIHR) Bristol Biomedical Research Centre (NIHR 203315). GMK, TRG and AMM acknowledge funding support from the Medical Research Council (The ImmunoMIND Hub, MR/Z50354X/1). AMM is supported by the Wellcome Trust (220857/Z/20/Z) and UKRI (MR/W014386/1). GDS, HJ, DR, GH, TRG, and GMK are supported by the National Institute for Health and Care Research Bristol Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. RG acknowledges funding support from the Swedish Research Council (VR2017-02900; 2022-00592). AH was supported by grants from the South-Eastern Norway Regional Health Authority (2020022, 2018059) and the Research Council of Norway (274611, 288083, 336085). This research was funded in part, by the Wellcome Trust. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and CD, GMK will serve as guarantors for the contents of this paper. Genomewide genotyping data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

ALSPAC data used as reference panel: ethical approval was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, and nurses. GWAS data: across all analyses summary data were used. These data are publicly available for research purposes. Details on the ethics declarations for each GWAS study can be found in the original publications.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes